These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38301349)

  • 1. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
    Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
    Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
    Christiansen SN; Horskjær Rasmussen S; Ostergaard M; Pons M; Michelsen B; Pavelka K; Codreanu C; Ciurea A; Glintborg B; Santos MJ; Sari I; Rotar Z; Gudbjornsson B; Macfarlane GJ; Relas H; Iannone F; Laas K; Wallman JK; van de Sande M; Provan SA; Castrejon I; Zavada J; Mogosan C; Nissen MJ; Loft AG; Barcelos A; Erez Y; Pirkmajer KP; Grondal G; Jones GT; Hokkanen AM; Chimenti MS; Vorobjov S; Di Giuseppe D; Kvien TK; Otero-Varela L; van der Horst-Bruinsma I; Hetland ML; Ørnbjerg LM
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
    Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML
    Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
    Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
    Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
    Michelsen B; Ørnbjerg LM; Kvien TK; Pavelka K; Nissen MJ; Nordström D; Santos MJ; Koca SS; Askling J; Rotar Z; Gudbjornsson B; Codreanu C; Loft AG; Kristianslund EK; Mann HF; Ciurea A; Eklund KK; Vieira-Sousa E; Yazici A; Jacobsson L; Tomšič M; Löve TJ; Ionescu R; van der Horst-Bruinsma IE; Iannone F; Pombo-Suarez M; Jones GT; Hyldstrup LH; Krogh NS; Hetland ML; Østergaard M
    Rheumatology (Oxford); 2020 Sep; 59(9):2455-2461. PubMed ID: 31960053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA.
    Gaffney K; Gullick N; MacKay K; Patel Y; Sengupta R; Sheeran T; Hemmings L; Pamies P
    Rheumatol Adv Pract; 2023; 7(3):rkad055. PubMed ID: 37663578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
    Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
    Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
    Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Jacobsson L; Loft AG; Iannone F; Fagerli KM; Vencovsky J; Santos MJ; Möller B; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Cefle A; Eklund K; Codreanu C; Jones G; van der Sande M; Wallman JK; Sebastiani M; Michelsen B; Závada J; Nissen MJ; Sanchez-Piedra C; Tomšič M; Love TJ; Relas H; Mogosan C; Hetland ML; Østergaard M
    J Rheumatol; 2024 Apr; 51(4):378-389. PubMed ID: 38224992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis - data from the Danish nationwide DANBIO registry.
    Mathew AJ; Glintborg B; Krogh NS; Hetland ML; Østergaard M
    Semin Arthritis Rheum; 2022 Feb; 52():151948. PubMed ID: 35027245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
    Michelsen B; Lindström U; Codreanu C; Ciurea A; Zavada J; Loft AG; Pombo-Suarez M; Onen F; Kvien TK; Rotar Z; Santos MJ; Iannone F; Hokkanen AM; Gudbjornsson B; Askling J; Ionescu R; Nissen MJ; Pavelka K; Sanchez-Piedra C; Akar S; Sexton J; Tomsic M; Santos H; Sebastiani M; Österlund J; Geirsson AJ; Macfarlane G; van der Horst-Bruinsma I; Georgiadis S; Brahe CH; Ørnbjerg LM; Hetland ML; Østergaard M
    RMD Open; 2020 Sep; 6(3):. PubMed ID: 32950963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Lindström U; Pavelka K; Yilmaz N; Favalli EG; Nissen MJ; Michelsen B; Vieira-Sousa E; Jones GT; Ionescu R; Relas H; Sanchez-Piedra C; Tomšič M; Geirsson AJ; van der Horst-Bruinsma I; Askling J; Loft AG; Nekvindova L; Direskeneli H; Iannone F; Ciurea A; Fagerli KM; Santos MJ; Macfarlane GJ; Codreanu C; Eklund K; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Rusman T; Østergaard M; Hetland ML
    J Rheumatol; 2023 Aug; 50(8):1009-1019. PubMed ID: 36455943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
    Christiansen SN; Ørnbjerg LM; Rasmussen SH; Loft AG; Askling J; Iannone F; Zavada J; Michelsen B; Nissen M; Onen F; Santos MJ; Pombo-Suarez M; Relas H; Macfarlane GJ; Tomsic M; Codreanu C; Gudbjornsson B; Van der Horst-Bruinsma I; Di Giuseppe D; Glintborg B; Gremese E; Pavelka K; Kristianslund EK; Ciurea A; Akkoc N; Barcelos A; Sánchez-Piedra C; Peltomaa R; Jones GT; Rotar Z; Ionescu R; Grondal G; Van de Sande MGH; Laas K; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2022 Aug; 61(9):3799-3807. PubMed ID: 34940840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis.
    Ramonda R; Lorenzin M; Chimenti MS; D'Angelo S; Marchesoni A; Selmi C; Lubrano E; Santo L; Luchetti Gentiloni MM; Atzeni F; Cauli A; Manara M; Rossini M; Foti R; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Luciano N; Ruzzon F; Fatica M; Fracassi E; Doria A; Foti R; Carletto A
    Front Immunol; 2024; 15():1435599. PubMed ID: 39076975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
    Dougados M; Lardy-Cléaud A; Desfleurs E; Claudepierre P; Goupille P; Ryussen-Witrand A; Saraux A; Tournadre A; Wendling D; Lukas C
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38428974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis.
    Weddell J; Din NRA; Harrison SR; Michelena X; McGonagle D; Barr A; Vandevelde C; Freeston J; Marzo-Ortega H
    Rheumatol Adv Pract; 2024; 8(1):rkae018. PubMed ID: 38435412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
    Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A
    Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis.
    Kiltz U; Keininger DL; Holdsworth EA; Booth N; Howell O; Modi N; Tian H; Conaghan PG
    Clin Rheumatol; 2022 Feb; 41(2):471-481. PubMed ID: 34800174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.